Terug
Dagbereik
€ 26,47
€ 27,49
52-Weeksbereik
€ 8,73
€ 30,33
Volume
2.939.270
50D / 200D Gem.
€ 25,80
/
€ 18,18
Vorige Slotkoers
€ 27,35
Quick Summary
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (633 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -110,4 | 0,2 |
| P/B | 4,1 | 2,8 |
| ROE % | -3,2 | 3,7 |
| Net Margin % | -592,0 | 3,9 |
| Rev Growth 5Y % | 5,1 | 10,0 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Hold
€ 31,50
+18.8%
Low: € 30,00
High: € 34,00
Forward WPA
-€ 1,12
Omzet Sch.
9,39M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 1,09
-€ 0,13 – € 5,07
|
2,99B | 2 |
| FY2029 |
€ 0,28
-€ 0,03 – € 1,29
|
1,74B | 4 |
| FY2028 |
-€ 1,00
-€ 1,48 – -€ 0,20
|
513,21M | 7 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-02-06 | -€ 0,30 | -€ 0,24 | +19,9% |
| 2025-11-10 | -€ 0,32 | -€ 0,28 | +12,4% |
| 2025-08-11 | -€ 0,25 | -€ 0,18 | +27,9% |
| 2025-05-29 | -€ 0,26 | -€ 0,22 | +16,5% |
| 2025-02-10 | -€ 0,24 | -€ 0,13 | +45,8% |
| 2024-11-12 | -€ 0,25 | -€ 0,29 | -17,4% |
| 2024-08-08 | -€ 0,24 | -€ 0,18 | +26,0% |
| 2024-05-30 | -€ 0,26 | -€ 0,23 | +13,0% |
Insider Trading Activity
Buy ratio (90d)
0.0%
20 transactions
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 13, 2026 |
QVT Financial LP
|
sell | 375.784 | € 26,49 | € 9.956.768,16 |
| Feb 12, 2026 |
QVT Financial LP
|
sell | 425.000 | € 26,72 | € 11.367.000,00 |
| Feb 11, 2026 |
QVT Financial LP
|
sell | 425.000 | € 26,67 | € 11.334.750,00 |
| Dec 17, 2025 |
QVT Financial LP
|
sell | 777.332 | € 23,05 | € 17.935.594,88 |
| Dec 16, 2025 |
QVT Financial LP
|
sell | 917.282 | € 22,93 | € 21.129.618,56 |
| Nov 20, 2025 |
Venker Eric
President & Immunovant CEO
|
other | 7.051 | € 20,27 | € 142.923,77 |
| Nov 19, 2025 |
QVT Financial LP
|
sell | 1.300.000 | € 20,25 | € 26.304.500,00 |
| Oct 20, 2025 |
MOMTAZEE JAMES C
|
grant | 789 | — | — |
| Oct 20, 2025 |
MOMTAZEE JAMES C
|
other | 158 | € 17,74 | € 2.802,92 |
| Sep 28, 2025 |
Pulik Richard
CFO
|
other | 2.341 | € 15,17 | € 35.512,97 |
| Jul 28, 2025 |
Pulik Richard
CFO
|
other | 1.919 | € 11,35 | € 21.780,65 |
| Jul 17, 2025 |
Epperly Melissa B,
|
grant | 1.609 | — | — |
| Jun 25, 2025 |
Gold Daniel Allen
|
other | 36.756.758 | — | — |
| Jun 25, 2025 |
MANCHESTER KEITH S
|
other | 17.389.525 | — | — |
| Jun 25, 2025 |
QVT Financial LP
|
other | 36.756.758 | — | — |
| Jun 20, 2025 |
Pulik Richard
CFO
|
other | 1.503 | € 11,45 | € 17.209,35 |
| May 20, 2025 |
Gline Matthew
CEO
|
other | 10.945 | € 11,04 | € 120.832,80 |
| Apr 17, 2025 |
MOMTAZEE JAMES C
|
grant | 1.379 | — | — |
| Apr 17, 2025 |
MOMTAZEE JAMES C
|
other | 276 | € 10,15 | € 2.801,40 |
| Apr 17, 2025 |
Epperly Melissa B,
|
grant | 1.847 | — | — |
Dividend History
Yield
0,00%
Payout Ratio
0,00%
Growth (3Y)
N/A
Growth (5Y)
N/A
No dividend history available.
Belangrijkste Punten
Revenue grew 5,12% annually over 5 years — modest growth
Earnings declined -103,95% over the past year
Debt/Equity of 0,02 — conservative balance sheet
Negative free cash flow of -844,05M
PEG of 0,41 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 16,31%
Groei
Revenue Growth (5Y)
5,12%
Revenue (1Y)-11,19%
Earnings (1Y)-103,95%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-3,23%
ROIC-15,72%
Net Margin-591,96%
Op. Margin-3453,32%
Veiligheid
Debt / Equity
0,02
Current Ratio33,47
Interest Coverage0,00
Waardering
P/E Ratio
-110,36
Forward P/EN/A
P/B Ratio4,05
EV/EBITDAN/A
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | -11,19% | Revenue Growth (3Y) | -31,14% |
| Earnings Growth (1Y) | -103,95% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | 5,12% | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 29,05M | Net Income (TTM) | -171,98M |
| ROE | -3,23% | ROA | -3,16% |
| Gross Margin | 96,86% | Operating Margin | -3453,32% |
| Net Margin | -591,96% | Free Cash Flow (TTM) | -844,05M |
| ROIC | -15,72% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | 0,02 | Current Ratio | 33,47 |
| Interest Coverage | 0,00 | ||
| Dividends | |||
| Dividend Yield | 0,00% | Payout Ratio | 0,00% |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -110,36 | Forward P/E | N/A |
| P/B Ratio | 4,05 | P/S Ratio | 653,30 |
| PEG Ratio | 0,41 | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 2020,77 | Fwd Earnings Yield | N/A |
| FCF Yield | -4,45% | ||
| Market Cap | 18,98B | Enterprise Value | 16,37B |
Income Statement
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | 29,05M | 32,71M | 61,28M | 55,29M | 23,80M |
| Net Income | -171,98M | 4,35B | -1,01B | -845,26M | -809,23M |
| EPS (Diluted) | -0,24 | 5,23 | -1,42 | -1,26 | -1,18 |
| Gross Profit | 28,14M | 31,11M | 48,15M | 46,32M | 21,74M |
| Operating Income | -1,00B | 4,50B | -1,18B | -1,35B | -1,07B |
Balance Sheet
Annual, most recent first
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Total Assets | 5,44B | 7,22B | 2,39B | 2,59B | 2,69B |
| Total Liabilities | 249,74M | 773,95M | 782,02M | 523,70M | 527,69M |
| Shareholders' Equity | 4,69B | 5,97B | 1,16B | 1,66B | 1,90B |
| Total Debt | 100,17M | 499,75M | 481,40M | 283,89M | 244,98M |
| Cash & Equivalents | 2,72B | 6,54B | 1,68B | 2,06B | 2,13B |
| Current Assets | 5,00B | 6,73B | 1,80B | 2,15B | 2,19B |
| Current Liabilities | 149,41M | 266,76M | 272,45M | 184,37M | 218,96M |